CERENOME, INC.
Close on Oct 19, 2026
- Market cap
- $11.38M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Oct 29, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 14, 2026 | After market close | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 15, 2026 | After market close | $1.00M | $-1.05 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 12, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 30, 2025 | After market close | $1.40M | $-0.04 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | After market close | $1.40M | $-0.01 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 30, 2025 | After market close | – | $-1.19 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 27, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | After market close | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 15, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 5, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on Aug 14, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| annualized run-rate of test orders | 2026 | 1,250 | Maintained |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Cerenome filed with the SEC
Corporate Presentation (NASDAQ:CNSY) September 30, 2026 Exhibit 99.1
Other events · EX-99.1 to Form 8-K
Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Cerenome Reports Second Quarter 2026 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
Plus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ Clinical Program and CNSide® Commercial Rollout
Results of operations · EX-99.1 to Form 8-K
Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Other events · EX-99.1 to Form 8-K
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ in Pediatric Malignant Gliomas
Other events · EX-99.1 to Form 8-K
Plus Therapeutics Announces Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ Clinical Program and CNSide® Commercial Rollout
Results of operations · EX-99.1 to Form 8-K
Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Plus Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq’s Minimum Bid
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Plus Therapeutics Reports Third Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
Plus Therapeutics Reports Second Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
Plus Therapeutics Reports First Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Plus Therapeutics Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Forward Looking Statement This presentation contains statements that may
Regulation FD disclosure · EX-99.1 to Form 8-K
Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
Plus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Plus Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
Plus Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
Plus Therapeutics Regains Compliance with Nasdaq Listing Requirements
Other events · EX-99.1 to Form 8-K
Plus Therapeutics Announces Reverse Stock Split
Charter or bylaw amendment · Shareholder vote results · Other events · EX-99.1 to Form 8-K
Plus Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
Results of operations · EX-99 to Form 8-K
Plus Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
Results of operations · EX-99 to Form 8-K
Plus Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
Plus Therapeutics Executes $17.6 Million Award Contract with Cancer
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Plus Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
Plus Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
Plus Therapeutics and Medidata Announce Expanded Clinical Trial Partnership
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Plus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
Plus Therapeutics Significantly Expands Investigational Oncology Drug Pipeline
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Plus Therapeutics Announces Positive Interim Data from ReSPECT -GBM Phase 1 Clinical Trial at the 2021 Society for Neuro-Oncology Annual Meeting
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Plus Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K